Department of Pediatrics, University of Chieti, Chieti, Italy.
Center of Excellence on Aging, Department of Pediatrics, "G. D'Annunzio" University Foundation, University of Chieti, Chieti, Italy.
Pediatr Pulmonol. 2019 Aug;54(8):1242-1249. doi: 10.1002/ppul.24360. Epub 2019 May 17.
We measured respiratory parameters in children with juvenile idiopathic arthritis (JIA) without clinical signs of respiratory involvement and assessed the influence of methotrexate (MTX) treatment and disease activity on lung function.
In 49 JIA children and 70 controls lung volumes by spirometry and body plethysmography, and lung diffusion for carbon monoxide (DLCO) with single-breath technique were evaluated.
DLCO was significantly different between JIA children and controls (P = .01), whereas no differences were found in flow expiratory volume in 1 second (FEV ), forced vital capacity (FVC), forced expiratory flow at 25% to 75% of FVC (FEF ), peak expiratory flow, total lung capacity, and residual volume. After dividing study JIA patients according to MTX treatment, a significant difference in DLCO was found among JIA patients treated with MTX and those treated with other drugs and controls (P < .001). A significant difference in DLCO was also found among JIA patients with active disease and those with inactive disease and controls (P = .003). Analysis of covariance showed a weak independent effect of MTX therapy on DLCO after adjusting for sex and height (P = .04). Furthermore, a negative correlation of DLCO with MTX cumulative dose and MTX treatment duration (r = -.58, P = .006; r = -.68, P = .001, respectively) was found, whereas there was no correlation between DLCO and disease activity (r = -.10; P = .51).
In JIA children MTX treatment seems to have a dose-dependent effect on lung function. For this reason in these patients, a regular assessment of lung function, especially with DLCO evaluation, is recommended.
我们测量了无呼吸受累临床症状的幼年特发性关节炎(JIA)患儿的呼吸参数,并评估了甲氨蝶呤(MTX)治疗和疾病活动度对肺功能的影响。
在 49 例 JIA 患儿和 70 例对照者中,通过肺活量计和体描法评估肺容积,通过单次呼吸技术评估一氧化碳肺弥散量(DLCO)。
JIA 患儿与对照组的 DLCO 存在显著差异(P = .01),而 1 秒用力呼气容积(FEV )、用力肺活量(FVC)、25%至 75%肺活量时的用力呼气流量(FEF )、呼气峰流速、肺总量和残气量在两组间无差异。根据 MTX 治疗将研究 JIA 患者分组后,发现 MTX 治疗组与其他药物治疗组和对照组之间的 DLCO 存在显著差异(P < .001)。活动期 JIA 患儿与非活动期 JIA 患儿及对照组之间的 DLCO 也存在显著差异(P = .003)。协方差分析显示,调整性别和身高后,MTX 治疗对 DLCO 有微弱的独立影响(P = .04)。此外,我们发现 DLCO 与 MTX 累积剂量和 MTX 治疗时间呈负相关(r = -.58,P = .006;r = -.68,P = .001),而与疾病活动度无相关性(r = -.10;P = .51)。
在 JIA 患儿中,MTX 治疗似乎对肺功能有剂量依赖性影响。因此,建议这些患者定期评估肺功能,尤其是进行 DLCO 评估。